Simplified Chinese

English

Home page

The 2026 Kangtai Biological Supplier Conference was successfully held, with the company joining forces with its partners to chart a new course for high-quality development.

Release date:

2026-03-24

Author:

Source:

Abstract

On March 20, 2026, Kantai Biologics held its 2026 Supplier Conference at Beijing Minhai Biotechnology Co., Ltd., a wholly owned subsidiary of Kantai Biologics, under the theme “Breaking Barriers, Seizing Opportunities, and Achieving Win-Win Collaboration.” The event brought together core supplier representatives from across the country to engage in in-depth discussions on industry development trends and ways to deepen strategic partnerships, working together to lay a solid foundation for the high-quality growth of the biopharmaceutical sector. As the biopharmaceutical industry accelerates its pace of innovation, it faces both challenges and opportunities; amid these changes lies the potential for a new wave of industrial upgrading. In his address, Mr. Du Weimin, Chairman of Kantai Biologics, emphasized: “A stable supply chain…”

March 2026 On the 20th of the month, Kantai Biologics hosted its 2026 Supplier Conference at Beijing Minhai Biotechnology Co., Ltd., a wholly owned subsidiary of Kantai Biologics, under the theme “Breaking Barriers, Seizing Opportunities, and Achieving Win-Win Collaboration.” The event brought together key supplier representatives from across the country to engage in in-depth discussions on industry development trends and the deepening of strategic partnerships, working together to lay a solid foundation for the high-quality growth of the biopharmaceutical sector.

At present, the biopharmaceutical industry is undergoing accelerated iteration, with both challenges and opportunities coexisting; amid this shifting landscape lies the potential for a complete overhaul of the sector. Kangtai Organism In his address, Chairman Du Weimin emphasized: “When the supply chain is stable, the industry is stable; when partners stand united, our endeavors flourish.” This core principle not only charts a clear course for the industry’s development but also serves as a guiding beacon for Kangtai. Organism Collaboration with supplier partners sets the tone. Looking ahead, he stated unequivocally that Kangtai Biological will remain committed to a quality-first, innovation-driven philosophy, working hand in hand with its suppliers to uphold quality standards, enhance operational efficiency, and expand into global markets—thereby achieving win-win outcomes across the value chain and driving high-quality development of the biopharmaceutical industry.

In his address, Zheng Haifa, General Manager of Minhai Biologics, a wholly owned subsidiary of Kangtai Biological, outlined the company’s competitive advantages and its strategic roadmap for the future. Mr. Zheng highlighted that the company has undertaken numerous national-level research projects, received provincial and ministerial science and technology awards, and successfully brought 12 vaccine products to market—among them, the quadrivalent vaccine and the dual‑carrier 13‑valent pneumococcal conjugate vaccine, both industry firsts. He also shared updates on international collaborations and plans for building R&D and manufacturing facilities, clearly articulating the company’s future direction. His remarks further bolstered suppliers’ confidence in partnering with Kangtai Biological, laying a solid foundation for deepening mutual cooperation.

Focus On key fronts such as supply chain optimization, quality control, and collaborative cost reduction, Jiang Ying, Director of Group Procurement at Kangtai Biological, provided an in-depth overview of the procurement system’s upgrade roadmap, outlining a clear action plan for enhanced collaboration between the two parties.

Guided by Chairman Du Weimin’s “Chain‑Collaboration for Win‑Win” strategic vision, the attendees focused on the development of the vaccine industry and the building of a biopharmaceutical value chain. Through in-depth insights shared by seasoned industry experts, they fostered consensus through vigorous intellectual exchange, contributing valuable perspectives to the strategy’s implementation and injecting fresh momentum into the sector’s growth.

The five prestigious awards—the “Quality Service Award,” the “Excellence in Quality Award,” the “Outstanding Contribution Award,” the “Distinguished Partner Award,” and the “Strategic Partner Award”—were announced one after another, bringing the conference to a thrilling climax. Each trophy bears the indelible mark of suppliers’ steadfast partnership with Kangtai Biological; every round of applause resonates with heartfelt gratitude and shared pride.

This time, 2026 The Kangtai Biological Suppliers’ Conference marks a milestone in the company’s journey, under the leadership of Chairman Du Weimin, as it brings together partners to forge consensus and map out a shared vision. Looking ahead, guided by President Du, Kangtai Biological and Minhai Biological will uphold the principle of win-win cooperation, remain steadfast in the core tenet that “a stable supply chain ensures industrial stability,” and work hand in hand with their supplier partners to break new ground, seize emerging opportunities, and jointly propel China’s biopharmaceutical industry into a new phase of higher‑quality development.

Keywords:

Reposted: Kangtai Biological attends the 2026 Vaccine and Health Conference; several innovative vaccine candidates have drawn significant attention from the industry.

Deepening Government–Enterprise Communication to Boost Industrial Development — Ai Li, Secretary of the Party Group and Director of the Standing Committee of the Daxing District People’s Congress, Led a Research Visit to Minhai Biotechnology.

Recommended Reading

Batch Release Status of the Company’s Products in 2026

The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.

Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.

Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09

Online Customer Service

Telephone

400 189 9806

Contact Information

Customer Service Hotline

4001899806

Phone number

010-59613600

Official Website

http://www.biominhai.com

Company Address

No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing

WeChat Official Account

Business license

Website Development: China Enterprise Dynamics

Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.